Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial
Li W, Onishi N, Newitt D, Gibbs J, Wilmes L, Jones E, Joe B, Sit L, Yau C, Chien A, Price E, Albain K, Kuritza T, Morley K, Boughey J, Brandt K, Choudhery S, Clark A, Rosen M, McDonald E, Elias A, Wolverton D, Fountain K, Euhus D, Han H, Niell B, Drukteinis J, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Asare S, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Berry D, DeMichele A, Abe H, Sheth D, Edmiston K, Ellis E, Ha R, Wynn R, Crane E, Dillis C, Nelson M, Church A, Isaacs C, Khan Q, Oh K, Jafarian N, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Sheth P, Hovanessian-Larsen L, Eghtedari M, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Goudreau S, Brown T, Esserman L, Hylton N. Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial. Cancer Research 2020, 80: pd9-04-pd9-04. DOI: 10.1158/1538-7445.sabcs19-pd9-04.Peer-Reviewed Original ResearchI-SPY 2 TRIALFunctional tumor volumeTumor volume progressionTumor progressionNon-pCRI-SPYTumor volumeHER2 subtypeVolume progressionCancer subtypesTumour progressorsEvaluate MRI changesI-SPY 2Triple negative subtypeHER2+ tumorsHigh-risk patientsNegative predictive valueBreast cancer subtypesEnhancement post-contrastTime pointsNumbers of patientsInsufficient image qualityTreatment time pointsPost-NACPre-NAC
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply